Skip to main content
Erschienen in: Clinical and Translational Oncology 10/2014

01.10.2014 | Research Article

Looking for complementary alternatives to CTCAE for skin toxicity in radiotherapy: quantitative determinations

verfasst von: A. González-Sanchís, A. Vicedo-González, L. Brualla-González, J. C. Gordo-Partearroyo, R. Iñigo-Valdenebro, J. Sánchez-Carazo, D. Granero-Cabañero, J. Roselló-Ferrando, J. López-Torrecilla

Erschienen in: Clinical and Translational Oncology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Radiotherapy (RT) is an essential part of the patient’s treatment diagnosed with cancer. Determination of the most common RT secondary effect, the cutaneous toxicity, is usually based on visual rating scales, like Common Terminology Criteria for Adverse Events with an inherent subjectivity. The aim of this work is to perform an objective method to evaluate the radiodermatitis using a non-invasive imaging technique based on laser Doppler flowmetry (LDF).

Materials and methods

A prospective study was performed analysing 1,824 measurements. A LDF was used to measure the cutaneous microcirculation in real time. A basal measurement was taken prior to radiotherapy treatment. To be able to observe the microcirculation changes related to the delivered dose, several sets of measurements were taken in the irradiated area along the RT treatment and in the contralateral non-irradiated area.

Results

A relative increase in blood flow at all measured points was found in the irradiated area. This relative increase in blood flow increases with the dose administered. In the non-irradiated contralateral area, the relative increase in blood flow is not significant and is independent of the dose administered. After treatment, a decrease in blood flow was detected with a trend towards returning to the baseline measurements.

Conclusions

LDF is an objective technique that assesses early radiodermatitis. This method is useful to develop strategies to prevent onset of radiation dermatitis in patients irradiated, such as the modification and individualization of fractionation parameters of the RT. This allows the reduction of radiation morbidities and maintains patient quality of life.
Literatur
1.
Zurück zum Zitat Bentzen SM, Dorr W, Anscher MS, Denham JW, Hauer-Jensen M, Marks LB, et al. Normal tissue effects: reporting and analysis. Semin Radiat Oncol. 2003;13:189–202.PubMedCrossRef Bentzen SM, Dorr W, Anscher MS, Denham JW, Hauer-Jensen M, Marks LB, et al. Normal tissue effects: reporting and analysis. Semin Radiat Oncol. 2003;13:189–202.PubMedCrossRef
2.
Zurück zum Zitat Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.PubMedCrossRef Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.PubMedCrossRef
3.
Zurück zum Zitat Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE): version 4.0. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda: Maryland; 2009. v4.02: 2009. Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE): version 4.0. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda: Maryland; 2009. v4.02: 2009.
4.
Zurück zum Zitat Freedman GM, Anderson PR, Li J, Eisenberg DF, Hanlon AL, Wang L, et al. Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer. Am J Clin Oncol. 2006;29:66–70.PubMedCrossRef Freedman GM, Anderson PR, Li J, Eisenberg DF, Hanlon AL, Wang L, et al. Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer. Am J Clin Oncol. 2006;29:66–70.PubMedCrossRef
5.
Zurück zum Zitat Formenti S, Gidea-Addeo D, Goldberg J, Roses D, Guth A, Rosenstein B, et al. Phase I–II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol. 2007;25:2236–42.PubMedCrossRef Formenti S, Gidea-Addeo D, Goldberg J, Roses D, Guth A, Rosenstein B, et al. Phase I–II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol. 2007;25:2236–42.PubMedCrossRef
6.
Zurück zum Zitat Pommier P, Gomez F, Sunyach MP, D’Hombres A, Carrie C, Montbarbon X. Phase III randomized trial of calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. J Clin Oncol. 2004;22:1447–53.PubMedCrossRef Pommier P, Gomez F, Sunyach MP, D’Hombres A, Carrie C, Montbarbon X. Phase III randomized trial of calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. J Clin Oncol. 2004;22:1447–53.PubMedCrossRef
7.
Zurück zum Zitat Mukesh M, Harris E, Jena R, Coles Ch. Relationship between irradiated breast volume and late normal tissue complications. A systematic review. Radiother Oncol. 2012;104:1–10.PubMedCrossRef Mukesh M, Harris E, Jena R, Coles Ch. Relationship between irradiated breast volume and late normal tissue complications. A systematic review. Radiother Oncol. 2012;104:1–10.PubMedCrossRef
8.
Zurück zum Zitat Pigno J, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckham W, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008;26:2085–92.CrossRef Pigno J, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckham W, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008;26:2085–92.CrossRef
9.
Zurück zum Zitat Bonner RF, Clem TR, Bowen PD. Laser Doppler continuous real-time monitor of pulsatile and mean blood flow in tissue microcirculation. In: Chen SH, Chu B, Nossal R, editors. Scattering techniques applied to supramolecular and non-equilibrium systems. New York: Plenum Press; 1981. p. 685–701.CrossRef Bonner RF, Clem TR, Bowen PD. Laser Doppler continuous real-time monitor of pulsatile and mean blood flow in tissue microcirculation. In: Chen SH, Chu B, Nossal R, editors. Scattering techniques applied to supramolecular and non-equilibrium systems. New York: Plenum Press; 1981. p. 685–701.CrossRef
10.
Zurück zum Zitat Bonner R, Nossal R. Model for laser Doppler measurements of blood flow in tissue. Appl Opt. 1981;20:2097–107.PubMedCrossRef Bonner R, Nossal R. Model for laser Doppler measurements of blood flow in tissue. Appl Opt. 1981;20:2097–107.PubMedCrossRef
11.
Zurück zum Zitat Saumet JL, Dittmar A, Leftheriotis G. Non-invasive measurement of skin blood flow: comparison between plethysmography, laser Doppler flowmeter and heat thermal clearance method. Int J Microcirc Clin Exp. 1986;5:73–83.PubMed Saumet JL, Dittmar A, Leftheriotis G. Non-invasive measurement of skin blood flow: comparison between plethysmography, laser Doppler flowmeter and heat thermal clearance method. Int J Microcirc Clin Exp. 1986;5:73–83.PubMed
12.
Zurück zum Zitat Fagrell B. Advances in microcirculation network evaluation: an update. Int J Microcirc Clin Exp. 1995;15(Suppl 1):34–40.PubMedCrossRef Fagrell B. Advances in microcirculation network evaluation: an update. Int J Microcirc Clin Exp. 1995;15(Suppl 1):34–40.PubMedCrossRef
13.
Zurück zum Zitat Chufa HE, Cherry GW. Blood flow in patients with leg ulcers. In: Mani R, Falanga V, Shearman CP, Sandeman D, editors. Chronic wound healing. Clinical measurement and basic science. London: W.B. Saunders; 2000. Chufa HE, Cherry GW. Blood flow in patients with leg ulcers. In: Mani R, Falanga V, Shearman CP, Sandeman D, editors. Chronic wound healing. Clinical measurement and basic science. London: W.B. Saunders; 2000.
14.
Zurück zum Zitat Romanelli M, Falanga V. Measurement of transcutaneous oxygen tension in chronic wounds. In: Mani R, Falanga V, Shearman CP, Sandeman D, editors. Chronic wound healing. Clinical measurement and basic science. London: W.B. Saunders; 2000. Romanelli M, Falanga V. Measurement of transcutaneous oxygen tension in chronic wounds. In: Mani R, Falanga V, Shearman CP, Sandeman D, editors. Chronic wound healing. Clinical measurement and basic science. London: W.B. Saunders; 2000.
15.
Zurück zum Zitat Bland JM, Altman DG. Statistical methods for assessing agreement between measurement. Biochim Clin. 1987;11:399–404. Bland JM, Altman DG. Statistical methods for assessing agreement between measurement. Biochim Clin. 1987;11:399–404.
16.
Zurück zum Zitat Evaluation of measurement data—guide to the expression of uncertainty in measurement. JCGM. 2008;100. Evaluation of measurement data—guide to the expression of uncertainty in measurement. JCGM. 2008;100.
17.
Zurück zum Zitat Schnur JB, Love B, Scheckner BL, Green S, Wernicke AG, Montgomery GH. A systematic review of patient-rated measures of radiodermatitis in breast cancer radiotherapy. Am J Clin Oncol. 2011;34:529–36.PubMedPubMedCentral Schnur JB, Love B, Scheckner BL, Green S, Wernicke AG, Montgomery GH. A systematic review of patient-rated measures of radiodermatitis in breast cancer radiotherapy. Am J Clin Oncol. 2011;34:529–36.PubMedPubMedCentral
18.
Zurück zum Zitat Feight D, Baney T, Bruce S, McQuestion M. Evidence-based interventions for radiation dermatitis. Clin J Oncol Nurs. 2011;15(5):481–92.PubMedCrossRef Feight D, Baney T, Bruce S, McQuestion M. Evidence-based interventions for radiation dermatitis. Clin J Oncol Nurs. 2011;15(5):481–92.PubMedCrossRef
19.
Zurück zum Zitat Archambeau JO, Pezner R, Wasserman T. Pathophysiology of irradiated skin and breast. Int J Radiat Oncol Biol Phys. 1995;31:1171–85.PubMedCrossRef Archambeau JO, Pezner R, Wasserman T. Pathophysiology of irradiated skin and breast. Int J Radiat Oncol Biol Phys. 1995;31:1171–85.PubMedCrossRef
20.
Zurück zum Zitat Chren MM, Lasek RJ, Sahay AP, Sands L. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105–10.PubMedCrossRef Chren MM, Lasek RJ, Sahay AP, Sands L. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105–10.PubMedCrossRef
21.
Zurück zum Zitat Atherton PJ, Burger KN, Loprinzi CL, Neben Wittich MA, Miller RC, Jatoi A, et al. Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled analysis (N0993). Support Care Cancer. 2012;20(8):1729–35.PubMedCrossRefPubMedCentral Atherton PJ, Burger KN, Loprinzi CL, Neben Wittich MA, Miller RC, Jatoi A, et al. Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled analysis (N0993). Support Care Cancer. 2012;20(8):1729–35.PubMedCrossRefPubMedCentral
22.
Zurück zum Zitat Lim CC, Devi MK, Ang E. Anxiety in women with breast cancer undergoing treatment: a systematic review. Int J Evid Based Healthc. 2011;9(3):215–35.PubMed Lim CC, Devi MK, Ang E. Anxiety in women with breast cancer undergoing treatment: a systematic review. Int J Evid Based Healthc. 2011;9(3):215–35.PubMed
23.
Zurück zum Zitat Bostrom A, Lindman H, Swartling C, Berne B, Bergh J. Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study. Radiother Oncol. 2001;59:257–65.PubMedCrossRef Bostrom A, Lindman H, Swartling C, Berne B, Bergh J. Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study. Radiother Oncol. 2001;59:257–65.PubMedCrossRef
24.
Zurück zum Zitat Dornfeld K, Gessert CE, Renier CM, McNaney DD, Urias RE, Knowles DM, et al. Differences in breast tissue oxygenation following radiotherapy. Radiother Oncol. 2011;100:289–92.PubMedCrossRef Dornfeld K, Gessert CE, Renier CM, McNaney DD, Urias RE, Knowles DM, et al. Differences in breast tissue oxygenation following radiotherapy. Radiother Oncol. 2011;100:289–92.PubMedCrossRef
Metadaten
Titel
Looking for complementary alternatives to CTCAE for skin toxicity in radiotherapy: quantitative determinations
verfasst von
A. González-Sanchís
A. Vicedo-González
L. Brualla-González
J. C. Gordo-Partearroyo
R. Iñigo-Valdenebro
J. Sánchez-Carazo
D. Granero-Cabañero
J. Roselló-Ferrando
J. López-Torrecilla
Publikationsdatum
01.10.2014
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 10/2014
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1163-0

Weitere Artikel der Ausgabe 10/2014

Clinical and Translational Oncology 10/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.